ClinicalTrials.gg
Enrolling by invitationNCT07488663Updated Mar 23, 2026

MODELING OBSESSIVE COMPULSIVE DISORDER AND EXPLORING TREATMENT RESPONSE USING INNOVATIVE THERAPIES AND STEM CELLS

An interventional study of deep transcranial magnetic stimulation (dTMS) and Theta burst stimulation (TBS) in Obsessive - Compulsive Disorder, sponsored by ASST Fatebenefratelli Sacco. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by ASST Fatebenefratelli Sacco · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Apr 2023, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Obsessive-Compulsive Disorder with a site in Italy — 5 open to participants now, 6 under way, none of them phase 3. Obsessive-Compulsive Disorder · Italy.

Planned enrollment
4th of 10
60 · median 37
Started
2023
with 1 other
No phase
3 of 14
2 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
ASST Fatebenefratelli Sacco

Among the 14 studies in Obsessive-Compulsive Disorder with a site in Italy, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 with no phase, and was the 12th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

5 of the 14 studies in Obsessive-Compulsive Disorder with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Obsessive-Compulsive Disorder with a site in Italy, or all of them as a file.
02

Study summary

This study focuses on people with obsessive-compulsive disorder (OCD) who do not respond well to standard treatments. Researchers aim to understand why some patients respond to medications or brain stimulation therapies, while others do not. The study will include 60 patients grouped by their treatment response:

  1. Those who respond to medications
  2. Those who respond to transcranial magnetic stimulation (TMS)
  3. Those who do not respond to either Blood samples will be used to create nerve cells in the lab, allowing scientists to study how these cells react to treatments and brain stimulation. By combining clinical information with lab findings, the goal is to discover biological markers that predict which therapy will work best for each person. This research hopes to improve personalized treatment options for OCD.
Read the detailed description

Adults (18-65 years old) with obsessive-compulsive disorder (OCD) recruited at two specialized clinics in Milan (Luigi Sacco Hospital) and Monza (IRCCS Fondazione San Gerardo Monza). After a complete explanation of the study, everyone will provide written informed consent and have a diagnostic interview to confirm OCD. People with seizures/epilepsy or certain implanted devices (e.g., pacemaker, intracranial metal clips) will not be enrolled.

Procedures:

  1. Initial assessments: Participants complete standard questionnaires and tests about OCD symptoms, mood, anxiety, and thinking (e.g., Y-BOCS, HDRS, HARS, MMSE, CANTAB, CGI). Basic information (age, sex, education, medical history, current medications) is collected in an anonymized electronic form.
  2. Grouping by medication response:

    Responders (20 people): OCD symptoms improve with serotonin reuptake inhibitors (SRIs).

    Treatment-resistant (40 people): OCD symptoms did not improve after multiple SRI trials (including SSRIs and clomipramine at recommended doses).

  3. Randomized brain stimulation for treatment-resistant OCD:

    The 40 treatment-resistant participants are randomly assigned (1:1) to Theta-Burst TMS (TBS) or Deep TMS (d-TMS), following established safety guidelines.

    Medications remain stable during TMS. Symptom changes are measured with the Y-BOCS at baseline and follow-up. Participants are classified as responders or non-responders to TBS or d-TMS.

    After treatment, people fall into five subgroups: SRI Responders, d-TMS Responders, TBS Responders, d-TMS Non-Responders, TBS Non-Responders.

  4. Blood samples and lab modeling:

    A small blood sample is used to create patient-derived stem cells (hiPSCs) and then striatal neurons (medium spiny neurons, MSNs) in the lab.

    These neurons help us study how brain cells from different patient groups respond to medicines and stimulation.

  5. Mimicking brain stimulation in the lab:

    Researchers use optogenetics (safe light pulses) to activate the lab-grown neurons, mirroring the effects of TMS.

    They also use well-known medicines that turn up or down dopamine signaling (e.g., D1/D2 agonists/antagonists) to see how neurons react.

    Changes in synaptic proteins and cell activity are measured with standard lab techniques.

  6. Gene activity (transcriptomics):

Using RNA sequencing, the team looks at which genes are "on" or "off" in neurons from different patient groups-before and after light stimulation-to discover molecular signatures linked to treatment response or resistance.

Findings are checked and confirmed with additional lab tests.

Study results analysis

The study includes 60 participants in total. Data are analyzed with standard statistical methods to compare groups and treatments. Lab experiments use multiple independent preparations to ensure reliable results.

Study outcomes:

By combining careful clinical assessments with cutting-edge cell models, this study aims to discover biological markers that can predict who will benefit from medicines and from innovative TMS protocols (TBS or d-TMS)-helping move toward more personalized care for OCD.

03

Conditions studied

  • Obsessive - Compulsive Disorder

Keywords

  • TRANSCRANIAL MAGNETIC STIMULATION
  • HUMAN PLURIPOTENT STEM CELLS
  • OBSESSIVE COMPULSIVE DISORDER
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of Obsessive-Compulsive Disorder (according to ; APA, 2013); both sexes; age ≥ 18 years and ≤ 65 years, ability to provide valid written ; for patients classified as responders to pharmacological treatment, a clinical history of at least one pharmacological trial with an SRI for a minimum of 6 weeks and evidence of treatment response, defined as a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score (Goodman et al., 1989) relative to the patient's baseline; for patients classified as resistant to pharmacological treatment [TR], clear evidence of treatment resistance, defined as the absence of a significant clinical response after at least two treatment trials with selective serotonin reuptake inhibitors (SSRIs) and one trial with clomipramine, each administered for a minimum of 12 weeks at the maximum recommended dose (Pallanti et al., 2002).

Exclusion criteria

Exclusion Criteria:

  • inability to provide ; no clinical history of treatment with SRI medications; clinical history of epilepsy or seizures; presence of a pacemaker, removable metal prostheses, implanted medical pumps, or intracranial metal clips.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Deep TMS

    This arm includes patients classified as resistant to pharmacological treatment, clear evidence of treatment resistance (defined as the absence of a significant clinical response after at least two treatment trials with SSRIs and one trial with clomipramine each administered for a minimum of 12 weeks at the maximum recommended dose). Patients will undergo d-TMS protocol for 5 weeks of daily treatments, 5 days a week and 4 treatments during the 6th week, and a 4-week follow-up phase.

    Device: deep transcranial magnetic stimulation (dTMS)

  • Experimental
    TBS protocol

    This arm includes patients classified as resistant to pharmacological treatment, clear evidence of treatment resistance (defined as the absence of a significant clinical response after at least two treatment trials with SSRIs and one trial with clomipramine each administered for a minimum of 12 weeks at the maximum recommended dose). Patients from this group will undergo the TBS protocol at the OCD clinic, ASST Fatebenefratelli Sacco of Milan, consisting in one week of daily treatments and a 4-weeks follow-up phase.

    Device: Theta burst stimulation (TBS)

Interventions

  • Devicedeep transcranial magnetic stimulation (dTMS)

    The d-TMS protocol will be performed at the treatment-resistant disorders clinic, IRCCS San Gerardo Monza, and will consist of 5 weeks of daily treatments, 5 days a week and 4 treatments during the 6th week, and a 4-week follow-up phase, following most recent clinical studies. d-TMS will be administered using a TMS stimulator equipped with an H-shaped coil (Harmelech et al., 2021). The coil will be placed 4 cm anterior to the foot motor cortex and used at 100% of the leg resting motor threshold (RMT), defined as the coil position that elicited the minimal involuntary contractions of the feet (3 of 6 attempts). The stimulation of the area localized 4 cm anterior to the foot motor cortex targets the dorsal medial prefrontal cortex (mPFC) and the anterior cingulate cortex (ACC) bilaterally. Patients will receive 20 Hz d-TMS at 100% of RMT, with 2-second pulse trains and 20-second intertrain intervals, for a total of 50 trains and 2,000 pulses per session.

  • DeviceTheta burst stimulation (TBS)

    TBS will be administered using a Magstim Rapid2 stimulator. 3-pulse 50-Hz bursts will be given to patients' left orbitofrontal cortex every 200 ms (at 5 Hz) at an intensity of 80% of the active motor threshold, defined as the coil position that elicited a right thumb movement while stimulating the left primary motor cortex. The treatment will consist of 2 sessions per day, thirty minutes apart, for 5 days in a week. Following the parameters of previous studies, each session will deliver a burst of three pulses at 50 Hz and repeated every 200 ms (at 5 Hz) for a total of 600 pulses lasting 40s (Oberman et al., 2011). A total of 1200 pulses will be delivered per day.

06

What researchers measure

Primary outcomes

  1. Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score

    The primary outcome is the change in Y-BOCS total score from baseline to the end of treatment, used to assess clinical response to TBS versus d-TMS in treatment-resistant OCD patients.

    Time frame: Baseline to 10 weeks (end of treatment and follow-up)

Secondary outcomes

  1. Clinical response rate

    Proportion of participants achieving a reduction ≥20% in Y-BOCS total score after TMS treatment.

    Time frame: Baseline to end of follow-up (4 weeks post-treatment)

  2. Change in Clinical Global Impression (CGI) scores

    Change in CGI-Severity and CGI-Improvement scores from baseline to post-treatment.

    Time frame: Baseline to 10 weeks

  3. Change in Hamilton Depression Rating Scale (HDRS)

    Change in depressive symptom severity measured by HDRS.

    Time frame: Baseline to end of follow-up (4 weeks post-treatment)

  4. Change in Hamilton Anxiety Rating Scale (HARS)

    Change in anxiety symptom severity measured by HARS.

    Time frame: Baseline to end of follow-up (4 weeks post-treatment)

  5. Molecular and cellular characterization of patient-derived neurons

    Assessment of morphological, biochemical, and transcriptomic profiles of hiPSC-derived medium spiny neurons from participants, including differential gene expression and response to stimulation.

    Time frame: From baseline (sample collection) to completion of laboratory analyses (up to 36 months)

  6. Treatment response classification

    Classification of participants into responders and non-responders to TBS or d-TMS based on predefined Y-BOCS thresholds.

    Time frame: Baseline to end of follow-up (4 weeks post-treatment)

07

Study locations

1 site
08

References and documents

Publications

  • Vadodaria KC, Ji Y, Skime M, Paquola A, Nelson T, Hall-Flavin D, Fredlender C, Heard KJ, Deng Y, Le AT, Dave S, Fung L, Li X, Marchetto MC, Weinshilboum R, Gage FH. Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. Mol Psychiatry. 2019 Jun;24(6):795-807. doi: 10.1038/s41380-019-0363-y. Epub 2019 Jan 30. PubMed 30700803 ↗
  • Shoaib M, Giacopuzzi E, Pain O, Fabbri C, Magri C, Minelli A, Lewis CM, Gennarelli M. Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression. Pharmacogenomics J. 2021 Feb;21(1):85-93. doi: 10.1038/s41397-020-00186-5. Epub 2020 Sep 17. PubMed 32943772 ↗
  • Burguiere E, Monteiro P, Feng G, Graybiel AM. Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. Science. 2013 Jun 7;340(6137):1243-6. doi: 10.1126/science.1232380. PubMed 23744950 ↗
  • Marcatili M, Marsoner F, D'Agostino A, Karnavas T, Bottai D, Scarone S, Conti L. Establishment of an induced pluripotent stem cell (iPSC) line from a patient with Clozapine-responder Schizophrenia. Stem Cell Res. 2016 Nov;17(3):630-633. doi: 10.1016/j.scr.2016.11.009. Epub 2016 Nov 9. PubMed 27934596 ↗
  • Marcatili M, Sala C, Dakanalis A, Colmegna F, D'Agostino A, Gambini O, Dell'Osso B, Benatti B, Conti L, Clerici M. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms. Ther Adv Psychopharmacol. 2020 Nov 2;10:2045125320968331. doi: 10.1177/2045125320968331. eCollection 2020. PubMed 33224469 ↗
  • Dell'Osso B, Mundo E, D'Urso N, Pozzoli S, Buoli M, Ciabatti M, Rosanova M, Massimini M, Bellina V, Mariotti M, Altamura AC. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord. 2009 Feb;11(1):76-81. doi: 10.1111/j.1399-5618.2008.00651.x. PubMed 19133969 ↗
  • Arici C, Benatti B, Cafaro R, Cremaschi L, Degoni L, Pozzoli S, Oldani L, Molteni L, Giorgetti F, Priori A, Vigano C, Dell'Osso B. A 6-month follow-up study on response and relapse rates following an acute trial of repetitive transcranial magnetic stimulation in patients with major depression. CNS Spectr. 2022 Feb;27(1):93-98. doi: 10.1017/S1092852920001807. Epub 2020 Sep 4. PubMed 32883389 ↗
  • Dell'Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Zohar J, Denys D, Altamura AC, Menchon JM. Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). CNS Spectr. 2015 Oct;20(5):469-73. doi: 10.1017/S1092852915000565. Epub 2015 Sep 9. PubMed 26349811 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 45 months is close to that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 23, 2026
StartActual
Apr 30, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Apr 29, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07488663
Lead sponsor
ASST Fatebenefratelli Sacco
Collaborators
Fondazione IRCCS San Gerardo dei Tintori, Istittuo ricerca carattere Sceintifico Fatenefratelli Brescia
Responsible party
BERNARDO DELL'OSSO (MD, FULL PROFESSOR OF PSYCHIATRY, ASST Fatebenefratelli Sacco) — Principal investigator
First posted
Mar 23, 2026
Start date
Apr 30, 2023
Primary completion
Jan 2027 (estimated)
Completion
Apr 29, 2027 (estimated)
Last update
Mar 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion